Disease · MONDO_0005212

rhabdomyosarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. rhabdomyosarcoma. Diseases, record MONDO_0005212. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005212

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: rhabdomyosarcoma; Open Targets
Open Targets ID: MONDO_0005212; Open Targets
Other names: rhabdomyosarcoma (disease), rhabdomyosarcoma, malignant; Open Targets
Disease Ontology: DOID:3247; Disease Ontology
MeSH: D012208; MeSH
NCI Thesaurus: C3359; NCI Thesaurus
Orphanet: ORPHA:780; Orphanet
Highest stage of its drugs: Phase 3, for 20 of its 95 drugs, from ClinicalTrials.gov; Open Targets

Drugs95

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	35	35	35	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
DACTINOMYCIN	CHEMBL1554	Protein	Phase 3	ClinicalTrials.gov	17	17	17	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	15	15	14	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
VINORELBINE	CHEMBL553025	Small molecule	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
VINCRISTINE SULFATE	CHEMBL501867	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
IRINOTECAN HYDROCHLORIDE	CHEMBL3989514	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 95

See all 95 drugs

Targets164

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	9	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 164

See all 164 targets

Trials102

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00354835	Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma	Phase 3	481	2017-07-25	Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Localized Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7	CYCLOPHOSPHAMIDE, DACTINOMYCIN, IRINOTECAN HYDROCHLORIDE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT00075582	Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma	Phase 3	390	2014-04-11	Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma	CYCLOPHOSPHAMIDE, DACTINOMYCIN, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT02567435	Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma	Phase 3	325	2024-10-01	Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma	CYCLOPHOSPHAMIDE, DACTINOMYCIN, IRINOTECAN HYDROCHLORIDE, TEMSIROLIMUS, VINCRISTINE SULFATE, VINORELBINE	Its record names the disease	ClinicalTrials.gov
NCT00642941	A Study of R1507 in Participants With Recurrent or Refractory Sarcoma	Phase 2	317	2021-02-03	Sarcoma	TEPROTUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01055314	Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma	Phase 2	175	2017-07-28	Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma	CIXUTUMUMAB, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, IFOSFAMIDE, IRINOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT00643565	A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.	Phase 2	154	2016-02-12	Sarcoma	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	Phase 1/2	140	2023-01-10	Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT04447755	A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)	Phase 2	127	2023-10-04	Relapsed or Refractory Solid Tumors	LENVATINIB	Its record names the disease	ClinicalTrials.gov
NCT01154816	Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia	Phase 2	118	2017-06-05	Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma	ALISERTIB	Its record names the disease	ClinicalTrials.gov
NCT00668148	A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma	Phase 2	113	2018-07-17	Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma, Adipocytic Sarcoma, Synovial Sarcoma	CIXUTUMUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 102

See all 102 trials

Comparisons in its trials24

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vincristine, Dactinomycin, Cyclophosphamide (VAC) vs VAC Alternating With VI: serious adverse events	4 of 222	11 of 226	448	NCT00354835	Trial comparisons
Regimen I (Chemotherapy, Radiotherapy) vs Regimen II (Chemotherapy, Radiotherapy, Surgery): serious adverse events	1 of 272	1 of 70	342	NCT00075582	Trial comparisons
IMC-A12 vs Temozolomide: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0	89 of 96	61 of 70	166	NCT01055314	Trial comparisons
Group 1 (Chemotherapy, Radiation Therapy, Cixutumumab) vs Group 2 (Chemotherapy, Radiation Therapy, Temozolomide): serious adverse events	79 of 96	40 of 70	166	NCT01055314	Trial comparisons
Chemotherapy vs Bevacizumab + Chemotherapy: deaths from any cause	40 of 79	37 of 71	150	NCT00643565	Trial comparisons
Chemotherapy vs Bevacizumab + Chemotherapy: serious adverse events	68 of 79	66 of 71	150	NCT00643565	Trial comparisons
Regimen A vs Regimen B: serious adverse events	35 of 44	32 of 42	86	NCT01222715	Trial comparisons
Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: Toxicity	6 of 6	24 of 26	32	NCT00923351	Trial comparisons
Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: deaths from any cause	0 of 6	1 of 26	32	NCT00923351	Trial comparisons
Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: serious adverse events	6 of 6	12 of 26	32	NCT00923351	Trial comparisons

1 to 10 of 24

See all 24 comparisons in its trials

Papers from its trials50

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31595663	RESULT	1	PubMed
22665534	RESULT	1	PubMed
22104356	RESULT	1	PubMed
22088484	RESULT	1	PubMed
21357783	RESULT	1	PubMed
20338746	RESULT	1	PubMed
19533657	RESULT	1	PubMed
19451433	RESULT	1	PubMed
18286501	RESULT	1	PubMed
17264331	RESULT	1	PubMed

1 to 10 of 50

See all 50 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005212

GET https://conductscience.org/api/diseases/v1/MONDO_0005212/drugs?page=2

API reference For AI assistants